Packing containers of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk on Wednesday posted second-quarter gross sales broadly according to expectations, after final week reducing its full-year steering and asserting its new CEO.
General revenues rose 13% year-on-year at fixed trade charges to 76.86 billion Danish kroner ($11.92 billion) over the interval, simply forward of the 76.6 billion Danish kroner forecast.
Quarterly web revenue got here in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts anticipated.
This can be a growing story. Please test again for updates.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be a part of our rising neighborhood at nextbusiness24.com
